emmaus life sciences inc quotes  news  google financecookies help us deliver our services by using our services you agree to our use of cookieslearn moregot itmy accountsearchmapsyoutubeplaynewsgmaildrivecalendargoogletranslatephotosmoreshoppingwalletfinancedocsbooksbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinanceemmaus life sciences inccompanysummarynewsrelated companiesmarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   emmaus life sciences inc   officers and directors peter ludlum co president and chief business officer charles stark senior vice president research and development lan tran chief administrative officer address  hawthorne blvd ste torrance ca usa  phone website links wwwemmausmedicalcom emmaus is ready to find a glut of uses for glutamine the pharmaceutical firm has one prescriptionstrength dosage of the amino acid lglutamine on the market and one in development nutrestore is a powder form of lglutamine used to treat short bowel syndrome while the company has also been testing lglutamine to treat sickle cell disease in  its endari treatment was approved by the fda to treat sickle cell disease in adults and children five years of age and older subsidiary newfield nutrition sells lglutamine as a nutritional supplement under the brand aminopure at stores in the us and through importers and distributors in japan and taiwan in early  generex biotechnology announced plans to acquire a  stake in emmaus more from hoovers » related companies name exchange symbol last trade change mkt cap emmaus life sciences inc private semafore pharmaceuticals inc private ferring pharmaceuticals inc private app pharmaceuticals llc private janssen biotech inc private grifols shared services north america inc private genentech inc private unitao pharmaceuticals llc private allermed laboratories inc private prometheus laboratories inc private mission pharmacal company private google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service emmaus life sciences inc private company information  bloomberg july    am et pharmaceuticals company overview of emmaus life sciences inc snapshot people company overview emmaus life sciences inc engages in the discovery development and commercialization of treatments and therapies primarily for rare and orphan diseases the company’s lead product candidate is an oral pharmaceuticalgrade lglutamine which has completed phase iii clinical trial for the treatment of sickle cell anemia and sickle ßthalassemia it also markets and sells nutrestore lglutamine powder for oral solution as a treatment for short bowel syndrome in patients receiving specialized nutritional support and sells lglutamine as a nutritional supplement under the aminopure brand name through retail stores in various states in the united states as well as through importers and distr emmaus life sciences inc engages in the discovery development and commercialization of treatments and therapies primarily for rare and orphan diseases the company’s lead product candidate is an oral pharmaceuticalgrade lglutamine which has completed phase iii clinical trial for the treatment of sickle cell anemia and sickle ßthalassemia it also markets and sells nutrestore lglutamine powder for oral solution as a treatment for short bowel syndrome in patients receiving specialized nutritional support and sells lglutamine as a nutritional supplement under the aminopure brand name through retail stores in various states in the united states as well as through importers and distributors in japan taiwan and south korea in addition the company engages in research focused on providing solutions for tissueengineering through the development of novel cell harvest methods and threedimensional living tissue replacement products for cell sheet therapy and regenerative medicine the company was formerly known as emmaus holdings inc and changed its name to emmaus life sciences inc in september  emmaus life sciences inc was founded in  and is headquartered in torrance california detailed description  hawthorne boulevardsuite torrance ca united statesfounded in  employees phone  fax  wwwemmausmedicalcom key executives for emmaus life sciences inc dr yutaka niihara md mph chairman  chief executive officer age  ms lan t tran mph copresident  chief administrative officer age  mr willis c lee ms vice chairman coo  cfo age  mr yasushi nagasaki cpa senior vice president of finance age  dr charles stark pharmd senior vice president of research  development age  compensation as of fiscal year  emmaus life sciences inc key developments us food and drug administration approves emmaus medical inc for patients age five years and older with sickle cell disease jul   us food and drug administration approved emmaus medical inc for patients age five years and older with sickle cell disease to reduce severe complications associated with the blood disorder sickle cell disease is an inherited blood disorder in which the red blood cells are abnormally shaped this restricts the flow in blood vessels and limits oxygen delivery to the bodys tissues leading to severe pain and organ damage according to the national institutes of health approximately  people in the united states have sickle cell disease the disease occurs most often in africanamericans latinos and other minority groups the average life expectancy for patients with sickle cell disease in the united states is approximately  to  years the safety and efficacy of endari were studied in a randomized trial of patients ages five to  years old with sickle cell disease who had two or more painful crises within the  months prior to enrollment in the trial patients were assigned randomly to treatment with endari or placebo and the effect of treatment was evaluated over  weeks patients who were treated with endari experienced fewer hospital visits for pain treated with a parenterally administered narcotic or ketorolac sickle cell crises on average compared to patients who received a placebo median  vs median  fewer hospitalizations for sickle cell pain median  vs median  and fewer days in the hospital median  days vs median  days patients who received endari also had fewer occurrences of acute chest syndrome a lifethreatening complication of sickle cell disease compared with patients who received a placebo  vs  endari received orphan drug designation for this use which provides incentives to assist and encourage the development of drugs for rare diseases in addition development of this drug was in part supported by the fda orphan products grants program which provides grants for clinical studies on safety andor effectiveness of products for use in rare diseases or conditions fda advisory committee recommends approval of endar from emmaus life sciences for the treatment of sickle cell disease may   emmaus life sciences inc announced that the oncologic drugs advisory committee of the us food and drug administration fda voted  to  that the overall benefitrisk profile of endaritm for the treatment of sickle cell disease scd is favorable the fda has set a pdufa target action date for july   if approved endari would be the first fdaapproved treatment for pediatric patients with scd and the first new treatment in almost  years for adult patients the therapy is an orallyadministered pharmaceutical grade lglutamine the fda is not bound by the committees recommendation but takes its advice into consideration when reviewing new drug applications endari has received orphan drug designation in the us orphan medicinal product designation in the eu and fast track designation from the fda emmaus life sciences inc receives notice of fda pdufa date for investigational lglutamine treatment for sickle cell disease nov   emmaus life sciences inc announced that the us food and drug administration has set a pdufa date of july   for a decision on the companys new drug application for its orallyadministered pharmaceutical grade lglutamine pglg product for the treatment for sickle cell disease the company also announced it will present data from a subgroup analysis of its phase  clinical trial with pglg treatment at the th american society of hematology annual meeting  exposition in san diego ca if approved by the fda pglg could be the first fdaapproved treatment for pediatric patients with sickle cell disease and the first new treatment in nearly  years for adult patients emmaus pglg therapy has received orphan drug designation in the us orphan medicinal product designation in the eu and fast track designation from the fda emmaus also plans to submit a marketing authorization application to the european medicines agency similar private companies by industry company name region st order pharmaceuticals inc united states st century animal health united states  buds organics llc united states p therapeutics llc united states ° pharmaceuticals llc united states recent private companies transactions typedate target mergeracquisition june   telcon co ltd mergeracquisition january    mergeracquisition october   kpm tech co ltd request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact emmaus life sciences inc please visit wwwemmausmedicalcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one emmaus life sciences inc receives notice of allowance for japanese patent for use of lglutamine in treatment of diabetes  the business journals menu select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita limited time offer subscribe now search × close sign in sign in your account your account welcome your account sign in existing users create your free account dont have an account your account subscriptions newsletters custom notifications my custom site manage site users sign out sign in sign in your account search home industries  topics all industries  topics banking  financial services career  workplace commercial real estate education energy food  lifestyle government  regulations health care manufacturing media  marketing philanthropy  nonprofits professional services residential real estate retailing sports business technology transportation travel  tourism sponsored content cre now we value your business office environments small business marketing know your neighborhood news news latest news business pulse press releases lists  awards lists all lists build your own lists people  companies companies top private companies find businesses for sale search for company news people people on the move contact top executives executive profiles search for people in the news events events business event calendar nominations more… jobs find or post a job store subscriptions reprints  more how to grow your business advance your career thought leadership trends tips and insights from our partners subscribers manage your account about  contact about the business journals advertise help  faqs call center directory apps  syndication newsletters acbj publications bizwomen upstart hemmings sports business journal inside lacrosse bostinno dcinno chicagoinno austininno select a city national albany albuquerque atlanta austin baltimore birmingham boston buffalo charlotte chicago cincinnati columbus dallas dayton denver greensborowinstonsalem honolulu houston jacksonville kansas city los angeles louisville memphis miamifort lauderdale milwaukee minneapolisst paul nashville new york orlando philadelphia phoenix pittsburgh portland raleighdurham sacramento san antonio san francisco seattle silicon valley st louis tampa bay washington dc wichita follow us twitter linkedin facebook google  press releases emmaus life sciences inc receives notice of allowance for japanese patent for use of lglutamine in treatment of diabetes  similar patent pending in the us  feb   am est torrance calif feb   prnewswire  emmaus announced today the allowance of patent application number  by the japanese patent office for the use of its lead investigative product pharmaceutical grade lglutamine pglg for the treatment of diabetes a related patent application is currently pending in the us and certain other jurisdictions  this represents a new potential indication for pglg which emmaus is currently developing for the treatment of sickle cell disease and diverticulosis the allowed japanese application reports a significant reduction of hbac levels one of the best indicators of whether diabetics and prediabetics have blood sugar levels under control through therapeutic application of lglutamine  the covered invention is directed to compositions for decreasing hbac levels in individuals who are shown to have average blood sugar levels in the diabetic range diabetes is a chronic disease that occurs when the pancreas is no longer able to make insulin or when the body cannot make good use of the insulin it produces people with diabetes have an increased risk of developing a number of serious health problems including cardiovascular disease kidney failure and blindness japan has more than  million diagnosed cases of diabetes which represents about  of japanese between the ages of  and   according to the us centers for disease control and prevention there are an estimated  million americans living with diabetes and an estimated  million americans with prediabetes a serious health condition that can increase a persons risk of developing type  diabetes this new patent allowance covering the use of pglg in diabetes further reinforces the utility of our lead product to treat a range of diseases where there is a medical need said yutaka niihara md mph chairman and ceo of emmaus we look forward to expanding our clinical program to further evaluate pglgs use in this new indication in addition to developing pglg for the treatment of diabetes and diverticulosis emmaus life sciences is seeking us food  drug administration fda approval to market the product for the treatment of sickle cell disease in adults and pediatric patients fda has set a pdufa date of july   for a decision on the companys new drug application for the use of pglg to treat sickle cell disease about emmaus life sciencesemmaus life sciences is engaged in the discovery development and commercialization of innovative treatments and therapies for rare diseases the companys research on sickle cell disease was initiated by yutaka niihara md mph chairman and ceo of emmaus at the los angeles biomedical research institute at harborucla medical center for more information please visit wwwemmauslifesciencescom forwardlooking statementsthis press release contains forwardlooking statements as that term is defined in the private securities litigation reform act of  regarding the research development and potential commercialization of pharmaceutical products such forwardlooking statements are based on current expectations and involve inherent risks and uncertainties including factors that could delay divert or change any of them and could cause actual outcomes and results to differ materially from current expectations additional risks and uncertainties are described in reports filed by emmaus life sciences inc with the us securities and exchange commission including its annual report on form k and quarterly reports on form q emmaus is providing this information as of the date of this press release and does not undertake any obligation to update any forwardlooking statements as a result of new information future events or otherwise   for more information contact media investors jim heins charles butler senior vice president senior vice president icr healthcare icr healthcare   jamesheinsicrinccom charlesbutlericrinccom     to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesemmauslifesciencesincreceivesnoticeofallowanceforjapanesepatentforuseoflglutamineintreatmentofdiabeteshtml source emmaus life sciences inc the information on this page is provided by pr newswire all rights reserved reproduction or redistribution of this content without prior written consent from pr newswire is strictly prohibited is not responsible for this content learn more about this service about pr newswire the information on this page is provided by pr newswire the business journals is not responsible for this content learn more microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft emmaus life sciences inc announces fda advisory committee meeting for endari™ for sickle cell emmaus life sciences inc announces fda advisory committee meeting for endari™ for sickle cell disease news provided by emmaus life sciences apr    et share this article torrance calif april   prnewswire  emmaus life sciences inc announced today that the oncologic drug advisory committee of the us food and drug administration fda has set a date of may   to review the companys new drug application nda for its orallyadministered pharmaceutical grade lglutamine product endari™ for the treatment of sickle cell disease the advisory committee meeting is an important step forward in the review process for this promising therapy said yutaka niihara md mph chairman and chief executive officer of emmaus life sciences we look forward to engaging in a productive discussion with the advisory committee members and continuing to work closely with the fda throughout the regulatory process   if approved endari would be the first fdaapproved treatment for pediatric patients with sickle cell disease and the first new treatment in nearly  years for adult patients endari has received orphan drug designation in the us orphan medicinal product designation in the eu and fast track designation from the fda the companys nda for endari was accepted for review by the fda in early november  with a target action date under the prescription drug user fee act set for july   about sickle cell diseasesickle cell disease is an inherited blood disorder characterized by the production of an altered form of hemoglobin which polymerizes and becomes fıbrous causing red blood cells to become rigid and change form so that they appear sickle shaped instead of soft and rounded patients with sickle cell disease suffer from debilitating episodes of sickle cell crises which occur when the rigid adhesive and inflexible red blood cells occlude blood vessels sickle cell crises cause excruciating pain as a result of insufficient oxygen being delivered to tissue referred to as tissue ischemia and inflammation these events may lead to organ damage stroke pulmonary complications skin ulceration infection and a variety of other adverse outcomes sickle cell disease is an orphan disease affecting approximately  patients in the us and millions worldwide with significant unmet medical needs about emmaus life sciencesemmaus life sciences is engaged in the discovery development and commercialization of innovative treatments and therapies for rare diseases the companys research on sickle cell disease was initiated by yutaka niihara md mph chairman and ceo of emmaus at the los angeles biomedical research institute at harborucla medical center for more information please visit wwwemmauslifesciencescom forwardlooking statementsthis press release contains forwardlooking statements as that term is defined in the private securities litigation reform act of  regarding the research development and potential commercialization of pharmaceutical products such forwardlooking statements are based on current expectations and involve inherent risks and uncertainties including factors that could delay divert or change any of them and could cause actual outcomes and results to differ materially from current expectations additional risks and uncertainties are described in reports filed by emmaus life sciences inc with the us securities and exchange commission including its annual report on form k and quarterly reports on form q emmaus is providing this information as of the date of this press release and does not undertake any obligation to update any forwardlooking statements as a result of new information future events or otherwise for more information contact media jim heinssenior vice presidenticr healthcarejamesheinsicrinccom investors charles butlersenior vice presidenticr healthcarecharlesbutlericrinccom to view the original version on pr newswire visithttpwwwprnewswirecomnewsreleasesemmauslifesciencesincannouncesfdaadvisorycommitteemeetingforendariforsicklecelldiseasehtml source emmaus life sciences related links httpwwwemmauslscom jan    et preview yutaka niihara md mph ceo of emmaus appointed executive chairman of generex biotechnology corporation my news release contains wide tables view fullscreen you just read emmaus life sciences inc announces fda advisory committee meeting for endari™ for sickle cell disease news provided by emmaus life sciences apr    et share this article looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search emmaus life sciences inc company profile  bloomberg feedback emmaus life sciences inc public company company profile sector health care industry biotech  pharma subindustry specialty pharma emmaus holdings inc is engaged in the discovery development and commercialization of treatments and therapies for rare diseases the companys primary focus is the latestage development of the amino acid lglutamine as a prescription drug for the treatment of sickle cell disease scd corporate information address  s western avenue suite  torrance ca  united states phone  fax  web url wwwemmausmedicalcom board members chairmanceo company yutaka niihara emmaus medical inc vice chairmancfocoo company willis lee emmaus life sciences inc board members company jon kuwahara novus therapeutics inc from the web press releases novus therapeutics announces change in management jul   novus therapeutics announces change in management jul   generex announces m convertible preferred stock financing first tranche satisfies emmaus deposit mar   generex provides update on deal to acquire controlling equity interest in emmaus life sciences inc feb   generex announces investor conference call jan   key executives yutaka niihara chairmanceo lan t tran copreschief administrative ofcrsecy willis c lee vice chairmancfocoo yasushi nagasaki senior vpfinance charles stark senior vpresearch  dev sponsored financial commentaries more from the web home news top headlines most popular exclusive law entrepreneurs leaders economy environment science sports markets magazine pursuits magazine bloomberg visual data bloomberg best and worst for comments or complaints about news coverage click here regions us china europe asia uk  ireland australia  new zealand canada india  pakistan japan africa eastern europe latin america middle east markets commodities currencies bonds stocks energy markets municipal bonds emerging markets funds islamic finance industries energy technology real estate finance health care transportation insurance retail media manufacturing quick market data stocks stock futures world indexes americas europe middle east  africa asiapacific gainers  losers earnings calendar industry leaders currencies americas europe middle east  africa asiapacific foreign exchange cross rates fx fixings currency converter forex trading videos commodities energy prices metals prices agricultural prices rates  bonds us treasuries uk gilts germany bunds japan bonds australia bonds bloomberg bond indexes corporate bonds consumer rates economic calendar watchlist european debt crisis symbol search the market now personal finance top headlines saving  investing real estate retirement planning financial advisers taxes blog ventured  gained real cost of money gallery calculators watchlist portfolio tracker tech top headlines social media mobile  wireless web enterprise tech tv games  movies apple tech deals global tech slideshows videos us politics sustainability top headlines energy corporate sustainability policy natural resources health  population slideshows videos blog the grid luxury top headlines autos billionaires living property travel well spent loot blog pursuits magazine videos tv live tv channel finder personalities apple tv ipad app schedule us asia europe shows surveillance market makers lunch money street smart bloomberg west game changers video must see latest live tv shows playlist radio live radio shows schedule personalities podcasts bloomberg brief featured podcasts and new shows bloomberg view masters in business first word surveillance bloomberg advantage in the loop bloomberg law taking stock bloomberg best more podcasts blogs global tech the grid loot the market now political capital tech deals ventured and gained opinion my saved registration sign in bloombergcom businessweekcom company about blog careers diversity  inclusion news mission philanthropy  engagement press room procurement sustainability products financial products bloomberg professional service bloomberg anywhere bloomberg tradebook bloomberg briefs bloomberg indexes bloomberg sef service center customer support enterprise products enterprise solutions trading solutions industry products bloomberg bna bloomberg government bloomberg law bloomberg link bloomberg new energy finance bloomberg sports content licensing bloomberg anywhere mobile apps bloomberg visual data emmaus life sciences inc  torrance  ca  company information products resources my account talk to a db advisor  business directory ca torrance pharmaceutical preparations pharmaceutical preparations emmaus life sciences inc e emmaus life sciences inc claim this business  hawthorne blvd b torrance ca  get directions   wwwemmausmedicalcom business info founded  incorporated annual revenue  employee count  industries pharmaceutical preparations contacts yutara nihara contact business your email address subject message send message company summary since  emmaus life sciences inc has been providing pharmaceutical preparations from torrance verified status unverified address unverified last verified  phone unverified payment method unverified view full report similar businesses nearby our similar businesses nearby shows similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile competitive landscape our competitive landscape shows how this business compares to similar businesses in their industry and region based on information found in their dun  bradstreet credibility review profile payments accepted no data hours sunday   monday   tuesday   wednesday   thursday   friday   saturday   e view additional data select from over  networks below to view available data about this business if this data is unavailable or inaccurate and you own or represent this business click here for more information on how you may be able to correct it credibility review google facebookcom yellowbookcom bingcom yellowpagescom merchantcircle tele atlas tomtom twittercom aol mapquest yahoo local applesiri groupon hotfrogcom comcastnet search reachlocal admedia dealsplus shoptopiacom alteryx dogtime media kslcom sirtune americantownscom driverside kudzucom specialsagentcom answerscom egood lawinfocom spotlikescom anywhocom egumball likenesscom spotzot eservicelog mapmyrun technocom apartmentguidecom ezlocalcom eztousecom teleroute aroundmecom metropolistcom therapistscom atlanta newhomes findlawcom time out new york avantar findthebestcom mojopagescom bb yellowpages fivestar software mycitywaycom tripadvisor bckyrdcom giftcardscom mycouponscom beachcaliforniacom golocalcom mymovecom upmesocialcom belo goodinfo newsgazette nokia usdirectorycom carscom nomao centzycom hibu openlistcom chacha search homeplatecom ownlocalcom visikard challamacom homestore patchcom voltari citybot pelopidas vouchd classifiedads hostway placeiq walkscorecom cloudmade hoodoyou planetdiscovercom weddingwirecom powerprofiles where inc contractorscom igolocalcom radiate media wikiocity couponmap indeedcom wimgocom crowdspot innova electronics intellistrand realtorcom datasphere inthemocom replycom yellowbotcom jiwire rocket fuel yellowpagecitycom dmvorg justclicklocalcom dirxion keencom zidstercom photos business credit report receive a onetime comprehensive credit report on this company get full credit report facebook twitter yelp call  to speak with a db advisor today customer resources products education center business articles  insights glossary contact us customer support communication preferences search for db duns our company about us company history business credit history careers press releases news success stories hoovers our network partners affiliates blog access to capital entrepreneurial initiative db international supplieredge site links business directory site map pipeda privacy policy website terms of service product license agreement  dun  bradstreet inc  all rights reserved emmaus life sciences inc clinical trial for sickle cell anemia emmaus medical inc  torrance california  nutrestore zorbtive aminopure  treatments for short bowel and sickle cell disease overview mission leadership management team board of directors corporate compliance corporate governance products nutrestore pipeline cell sheet engineering sickle cell disease more information bibliography review articles for patients sickle cell disease short bowel syndrome news press releases media contacts investors career contact us news the us food  drug administration approves endari™ lglutamine oral powder the first and only treatment for sickle cell disease in pediatric patients and first in nearly  years for adults  read more fda advisory committee recommends approval of endari™ from emmaus life sciences for the treatment of sickle cell disease  read more emmaus life sciences inc announces fda advisory committee meeting for endari™ for sickle cell disease  read more features sickle cell disease scd is an inherited blood disorder that affects red blood cells red blood cells contain hemoglobin which allows red blood cells to carry oxygen from the air in the lungs to all parts of the body continue reading emmaus medical inc registered ® emmaus medical inc torrance ca all rights reserved site by magellannet privacy terms of use contact emmaus medical inc  torrance california  nutrestore zorbtive aminopure  treatments for short bowel and sickle cell disease emmaus life sciences inc clinical trial for sickle cell anemia emmaus medical inc  torrance california  nutrestore zorbtive aminopure  treatments for short bowel and sickle cell disease overview mission leadership management team board of directors corporate compliance corporate governance products nutrestore pipeline cell sheet engineering sickle cell disease more information bibliography review articles for patients sickle cell disease short bowel syndrome news press releases media contacts investors career contact us news the us food  drug administration approves endari™ lglutamine oral powder the first and only treatment for sickle cell disease in pediatric patients and first in nearly  years for adults  read more fda advisory committee recommends approval of endari™ from emmaus life sciences for the treatment of sickle cell disease  read more emmaus life sciences inc announces fda advisory committee meeting for endari™ for sickle cell disease  read more features sickle cell disease scd is an inherited blood disorder that affects red blood cells red blood cells contain hemoglobin which allows red blood cells to carry oxygen from the air in the lungs to all parts of the body continue reading emmaus medical inc registered ® emmaus medical inc torrance ca all rights reserved site by magellannet privacy terms of use contact emmaus medical inc  torrance california  nutrestore zorbtive aminopure  treatments for short bowel and sickle cell disease overview emmaus medical inc  torrance california  nutrestore zorbtive aminopure  treatments for short bowel and sickle cell disease overview mission leadership management team board of directors corporate compliance corporate governance products nutrestore pipeline cell sheet engineering sickle cell disease more information bibliography review articles for patients sickle cell disease short bowel syndrome news press releases media contacts investors career contact us overview overview emmaus life sciences inc is a biopharmaceutical company engaged in the discovery development and commercialization of innovative treatments and therapies primarily for rare and orphan disease  we are initially focusing our product development efforts in sickle cell disease a genetic disorder  our lead product candidate is an oral pharmaceutical grade lglutamine treatment that demonstrated positive clinical results in our completed phase  clinical trial for sickle cell anemia and sickle ßthalassemia overview mission leadership management team board of directors corporate compliance corporate governance emmaus medical inc registered ® emmaus medical inc torrance ca all rights reserved site by magellannet privacy terms of use contact emmaus medical inc  torrance california  nutrestore zorbtive aminopure  treatments for short bowel and sickle cell disease media contacts emmaus medical inc  torrance california  nutrestore zorbtive aminopure  treatments for short bowel and sickle cell disease overview mission leadership management team board of directors corporate compliance corporate governance products nutrestore pipeline cell sheet engineering sickle cell disease more information bibliography review articles for patients sickle cell disease short bowel syndrome news press releases media contacts investors career contact us media contacts media contacts media inquiries david polkinventiv healthdavidpolkinventivhealthcom   news press releases media contacts emmaus medical inc registered ® emmaus medical inc torrance ca all rights reserved site by magellannet privacy terms of use contact emmaus medical inc  torrance california  nutrestore zorbtive aminopure  treatments for short bowel and sickle cell disease corporate governance emmaus medical inc  torrance california  nutrestore zorbtive aminopure  treatments for short bowel and sickle cell disease overview mission leadership management team board of directors corporate compliance corporate governance products nutrestore pipeline cell sheet engineering sickle cell disease more information bibliography review articles for patients sickle cell disease short bowel syndrome news press releases media contacts investors career contact us corporate governance corporate governance the board of directors of emmaus life sciences inc the company sets high standards for the companys employees officers and directors implicit in this philosophy is the importance of sound corporate governance it is the duty of the board of directors to serve as a prudent fiduciary for stockholders and to oversee the management of the companys business to fulfill its responsibilities and to discharge its duty the board of directors follows the procedures and standards that are set forth in these guidelines these guidelines are subject to modification from time to time as the board of directors deems appropriate in the best interests of the company or as required by applicable laws and regulations    governance documents code of ethics pdf committee charters audit committee charter pdf compensation nominatingcorporate governance committee charter pdf overview mission leadership management team board of directors corporate compliance corporate governance emmaus medical inc registered ® emmaus medical inc torrance ca all rights reserved site by magellannet privacy terms of use contact emmaus medical inc  torrance california  nutrestore zorbtive aminopure  treatments for short bowel and sickle cell disease bibliography emmaus medical inc  torrance california  nutrestore zorbtive aminopure  treatments for short bowel and sickle cell disease overview mission leadership management team board of directors corporate compliance corporate governance products nutrestore pipeline cell sheet engineering sickle cell disease more information bibliography review articles for patients sickle cell disease short bowel syndrome news press releases media contacts investors career contact us bibliography bibliography niihara y zerez cr akiyama d tanaka kr increased red cell glutamine availability in sickle cell anemia demonstration of increased active transport affinity and increased glutamine level in intact red cells j lab clin med   kim hs yospur l niihara y chronic lymphocytic leukemia in a patient with sickle cell anemia west j med ·  niihara y zerez cr akiyama ds tanaka kr oral lglutamine therapy for sickle cell anemia  subjective clinical improvement and favorable change in red cell nad redox potential am j hematol ·  niihara y shalev o hebbel rp wu h tu a akiyama ds tanaka kr desferal dfo conjugated with starch decreased nad redox potential of intact red blood cells rbc evidence for dfo as an extracellular inducer of oxidant stress in rbc am j hematol   lombard m xie y niihara y primary care management of sickle cell disease patients med am   curtis m leung m lam r saeed s gulati p niihara y successful treatment of a patient with pure red cell aplasia with prednisone cyclosporine and antithymocyte globulin med am   takasu j uykimpang r sunga ma amagase h niihara y aged garlic extract therapy for sickle cell anemia patients bmc blood disorders   niihara y ge j shalev o tanaka kr desferrioxamine decreases nad redox potential of intact red blood cells evidence for dfo as an inducer of oxidant stress in rbc bmc clinical pharmacology   niihara y matsui nm shen ym akiyama ds johnson cs sunga ma magpayo j embury sh kalra vk cho sh tanaka kr lglutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells bmc blood disorders   pipeline cell sheet engineering sickle cell disease more information bibliography review articles emmaus medical inc registered ® emmaus medical inc torrance ca all rights reserved site by magellannet privacy terms of use contact emmaus medical inc  torrance california  nutrestore zorbtive aminopure  treatments for short bowel and sickle cell disease corporate compliance emmaus medical inc  torrance california  nutrestore zorbtive aminopure  treatments for short bowel and sickle cell disease overview mission leadership management team board of directors corporate compliance corporate governance products nutrestore pipeline cell sheet engineering sickle cell disease more information bibliography review articles for patients sickle cell disease short bowel syndrome news press releases media contacts investors career contact us corporate compliance corporate compliance comprehensive compliance program introduction emmaus life sciences inc emmaus is committed to the development and commercialization of innovative treatments and therapies primarily for rare diseases our commitment is driven by corporate values that focus on integrity mutual respect and professionalism building trust among our customers and peers is critical to our success accordingly it is important that we conduct our business in compliance with all applicable legal and regulatory requirements our corporate code of conduct “code of conduct” is a statement of our fundamental principles of business conduct and ethical standards the code of conduct applies to all emmaus employees and contractors the code of conduct requires compliance with federal state and local laws and regulations wherever emmaus conducts business a copy of the code of conduct is available upon request in addition to the code of conduct each emmaus business sector has adopted policies and procedures designed to implement the general principles articulated in the code of conduct and in the healthcare compliance program these are corporate policies governing a broad range of topics included in this broad set of policies are specific policies and procedures that address the major risk areas discussed in the oig compliance program guidance for pharmaceutical manufacturers published by the us department of health and human services office of inspector general in may  hereinafter “oig compliance guidance” our compliance policies are also intended to be consistent with the provisions of the code on interactions with healthcare professionals published by the pharmaceutical research and manufacturers of america “phrma code” recognizing that compliance is a fundamental value and key asset of the company emmaus established a comprehensive healthcare compliance program that governs marketing sales and medical information activities our healthcare compliance program is consistent with the general principles of the oig guidance and the phrma code the oig guidance outlines seven elements that the oig considers fundamental to establishing a comprehensive compliance program these elements include designation of a compliance officer and compliance committee implementation of written policies and procedures education and training programs for all employees developing effective lines of communication between the compliance officer and all employees through hotlines or other means conducting internal monitoring and auditing enforcing standards through disciplinary guidelines and responding promptly to detected problems and undertaking corrective action as provided for in the oig guidance our program is tailored to the unique environment of the company compliance is a dynamic concept emmaus is committed to reviewing and enhancing its program at least annually to meet evolving compliance needs overview of the healthcare compliance program compliance officer and compliance committee the compliance officer “compliance officer” is charged with overall responsibility for the effectiveness of the healthcare compliance program the compliance officer is responsible either directly or through a designee for reporting on a regular basis to the board of directors on the status of the healthcare compliance program emmaus has a compliance committee consisting of representatives from selected functional areas of the company which is available to assist and advise the compliance officer with the implementation of the healthcare compliance program written policies and procedures the emmaus healthcare compliance program consists of written policies and procedures that provide requirements and restrictions on a range of activities by marketing sales and medical affairs personnel to ensure that their activities meet legal requirements and high ethical standards these policies which are separate from and in addition to emmaus corporate policies apply to all employees when they are involved in the marketing or sale of pharmaceutical products annual spending limit for california healthcare professionals as part of its healthcare compliance program emmaus adopted an annual spending limit for purposes of compliance with the requirements of california health and safety code sections  “california code” copies of the emmaus healthcare compliance program may be obtained by contacting emmaus at the following tollfree number  the declaration of compliance required by the california code is available on this web page emmaus established an annual limit not to exceed  in the aggregate on nonmonetary items or services including for example gifts promotional materials or items or activities that emmaus may give or otherwise provide to an individual medical or health care professional in accordance with the oig compliance guidance and with the phrma code  this limit on nonmonetary compensation includes educational or practicerelated items and meals associated with informational presentations or discussions which emmaus employees are permitted to provide to healthcare professionals under its healthcare compliance program policies emmaus’ annual limit does not include the following  drug samples given to physicians and health care professionals for free distribution to patients  financial support for independent medical education programs and financial support for health educational scholarships if the support is provided in a manner that conforms to the oig compliance guidance and the phrma code  payments made for legitimate professional services provided by a health care or medical professional including but not limited to consulting and other bona fide commercially reasonable and necessary services are exempt from the limit if the services are provided and paid at an amount that does not exceed the fair market value of the services rendered in accordance with and otherwise fully compliant with the oig compliance guidance and the phrma code emmaus’ policy on the annual limit on nonmonetary compensation has been communicated to employees in the emmaus sales  marketing section of the company each employee is expected to comply with the annual limits and with the restrictions and limitations imposed by the health care compliance program in accordance with the oig compliance guidance and the phrma code training and education an important component of the healthcare compliance program is the training program that communicates the company’s expectations concerning the ethical and legal obligation of emmaus personnel our code of conduct and corporate policies and procedures are distributed to employees the compliance officer oversees the content for the code of conduct and the healthcare compliance program training and the process to ensure it remains relevant and current all company personnel are required to complete annual training in compliance and the code of conduct in addition all emmaus sales  marketing employees are required to complete training on the healthcare compliance program as a condition of their employment these employees also undergo periodic retraining and remedial training if needed new fieldbased hires and existing fieldbased employees receive training and undergo an assessment to ensure compliance with federal laws and regulations and with the emmaus healthcare compliance program after this initial training periodic training of fieldbased employees is scheduled as needed on relevant policies fieldbased employees also receive training specific to the state law requirements of their service areas all employees engaged in marketing sales and medical information activities at the company’s headquarters receive training and undergo assessments this training is designed to ensure compliance with federal and state laws the emmaus healthcare compliance program and with the company code of conduct from time to time more specific compliance training is provided to employees at the company’s headquarters consistent with their roles and responsibilities within the company reporting mechanismsinternal lines of communication as part of our compliance culture each employee is expected to ensure that emmaus’ standards of conduct are met it is expected that employees will seek compliance guidance from their managers when it is needed and that employees will report information concerning a good faith belief of possible misconduct emmaus has a process that enables employees to report a good faith belief of suspected misconduct or any compliance issue through email or via a tollfree hotline that permits employees to report in a confidential fashion company policies prohibit retaliation or retribution of any kind following the good faith reporting of suspected misconduct or a compliance issue raising a concern under this policy will have no impact on any aspect of an employee’s employment all employees will continue to be held to the performance and policy standards that generally apply to emmaus employees it is expected that employees will not use this policy for improper purposes such as attempting to avoid accountability for the performance and policy standards that apply generally to emmaus’ employees monitoring and auditing consistent with its compliance commitment emmaus adopted monitoring and auditing processes to detect and investigate suspected breaches of its policies emmaus will take appropriate disciplinary action including dismissal where appropriate when behavior inconsistent with the company’s commitment to high ethical standards is detected the auditing plan is twofold and includes assessments focused on specific risk areas to evaluate whether the healthcare compliance program policies and procedures are being followed in addition an annual review of the healthcare compliance program is conducted to evaluate internal risk business practices and new regulatory requirements enforcing standards through disciplinary guidelines employees are expected to comply with the healthcare compliance program code of conduct company policies and procedures and applicable law and regulations the code of conduct makes it clear to all employees that when an employee’s conduct or behavior violates the standards and expectations set by emmaus appropriate disciplinary action up to and including dismissal may be taken each reported violation is handled on a casebycase basis based on the specific facts presented emmaus will undertake disciplinary action when appropriate to address inappropriate conduct addressing misconduct and developing corrective action as recognized in the oig guidance the implementation of a compliance program cannot guarantee that improper employee conduct will be entirely eliminated nonetheless it is our expectation that employees will comply with the company’s code of conduct and the policies established in support of our code in the event that emmaus becomes aware of violations of law or company policy we will investigate the matter and where appropriate take disciplinary action and implement corrective measures to prevent future violations annual declaration of compliance the california health and safety code section e requires that pharmaceutical companies declare annually in writing that the company is in compliance with the california code and with the company’s comprehensive compliance program  the california code further requires each pharmaceutical company to make its corporate compliance program and its annual written declaration of compliance available to the public on the pharmaceutical company’s web site  the california code also requires that the pharmaceutical company provide a toll free telephone number where a copy or copies of both of these documents may be obtained based on emmaus medical’s good faith understanding of the statutory requirements emmaus medical believes that its corporate compliance program meets the requirements of the health and safety code §§ the emmaus medical corporate compliance program was designed in accordance with the principles published by the us department of health and human services office of inspector general in may  as the oig compliance guidance and is also consistent with the provisions of the phrma code published by the pharmaceutical research and manufacturers of america in july  and revised in july  to obtain a copy of the corporate compliance program and a written declaration of the compliance please call   emmaus medical believes it complies with its corporate compliance program in all materials aspects dated january  overview mission leadership management team board of directors corporate compliance corporate governance emmaus medical inc registered ® emmaus medical inc torrance ca all rights reserved site by magellannet privacy terms of use contact emmaus medical inc  torrance california  nutrestore zorbtive aminopure  treatments for short bowel and sickle cell disease